<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949753</url>
  </required_header>
  <id_info>
    <org_study_id>PV4398</org_study_id>
    <nct_id>NCT01949753</nct_id>
  </id_info>
  <brief_title>Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder</brief_title>
  <acronym>P-EX</acronym>
  <official_title>Influence of Pregnenolone on Distress and Autonomic Parameters During Cognitive-behavioral Exposure Therapy in Patients With Obsessive-compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterization of the influence of pregnenolone vs. placebo on subjective distress and
      autonomic functioning during cognitive-behavioral exposure therapy in patients with
      obsessive-compulsive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main out-come parameters:

      Inter-session habituation as per SUD (100 mm VAS), Y-BOCS

      Secondary out-come parameter:

      HF/LF of HRV, Salivary epinephrine
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective units of distress (SUD)</measure>
    <time_frame>During exposure therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low/high frequency index of heart rate variability (L/HFI)</measure>
    <time_frame>During exposure therapy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Salivary cortisol, noradrenaline, pregnenolone; heart rate, blood pressure</measure>
    <time_frame>During exposure therapy</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obsessive-compulsive Disorder (OCD)</condition>
  <arm_group>
    <arm_group_label>Nutritional supplement Pregnenolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exposure therapy with pharmacological facilitation</intervention_name>
    <description>Exposure with response prevention and pharmacological facilitation</description>
    <arm_group_label>Nutritional supplement Pregnenolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exposure therapy</intervention_name>
    <description>Exposure with response prevention without pharmacological facilitation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -OCD according to DSM-IV criteria.

        Exclusion Criteria:

          -  Acute suicidality

          -  psychotic disorders,

          -  bipolar disorder

          -  substance dependency

          -  organic brain disorder

          -  pregnancy

          -  lactation

          -  tuberculosis

          -  gastric/duodenal ulcer

          -  diabetes mellitus

          -  acute inflammation

          -  autoimmune disorders

          -  arterial hypertension

          -  therapy with glucocorticoids (up to 4 weeks ago)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kellner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kellner, MD, PhD</last_name>
    <email>kellner@uke.uni-hamburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Kellner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obsessive-compulsive disorder (OCD)</keyword>
  <keyword>Exposure therapy</keyword>
  <keyword>Extinction learning</keyword>
  <keyword>Pregnenolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

